Bahl & Gaynor Inc. Purchases 9,189 Shares of Amdocs Limited $DOX

Bahl & Gaynor Inc. lifted its position in shares of Amdocs Limited (NASDAQ:DOX) by 1.7% during the third quarter, Holdings Channel reports. The firm owned 551,734 shares of the technology company’s stock after acquiring an additional 9,189 shares during the period. Bahl & Gaynor Inc.’s holdings in Amdocs were worth $45,270,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pzena Investment Management LLC increased its stake in Amdocs by 0.6% in the 3rd quarter. Pzena Investment Management LLC now owns 6,593,249 shares of the technology company’s stock valued at $540,976,000 after buying an additional 42,184 shares during the last quarter. LSV Asset Management grew its holdings in shares of Amdocs by 7.6% in the third quarter. LSV Asset Management now owns 3,648,703 shares of the technology company’s stock valued at $299,376,000 after acquiring an additional 257,193 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Amdocs by 3.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,111,312 shares of the technology company’s stock valued at $252,856,000 after acquiring an additional 91,428 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Amdocs by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,066,444 shares of the technology company’s stock worth $251,602,000 after acquiring an additional 9,207 shares during the period. Finally, Brandes Investment Partners LP boosted its position in Amdocs by 1.2% in the second quarter. Brandes Investment Partners LP now owns 2,328,804 shares of the technology company’s stock worth $212,481,000 after purchasing an additional 27,581 shares during the last quarter. 92.02% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus decreased their target price on Amdocs from $97.00 to $88.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of Amdocs in a report on Tuesday, January 27th. Bank of America lowered their price objective on shares of Amdocs from $100.00 to $97.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Wolfe Research reissued a “peer perform” rating on shares of Amdocs in a research report on Thursday, November 13th. Finally, Wall Street Zen raised shares of Amdocs from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Amdocs currently has an average rating of “Moderate Buy” and an average target price of $92.33.

Amdocs Stock Performance

Shares of DOX stock opened at $69.80 on Monday. The firm’s 50 day moving average is $77.63 and its 200 day moving average is $80.47. The stock has a market capitalization of $7.53 billion, a P/E ratio of 13.50, a PEG ratio of 1.23 and a beta of 0.42. Amdocs Limited has a 12 month low of $65.74 and a 12 month high of $95.41. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.23.

Amdocs (NASDAQ:DOX) last issued its earnings results on Tuesday, February 3rd. The technology company reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.06. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Amdocs had a net margin of 12.47% and a return on equity of 20.19%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.66 EPS. Amdocs has set its Q2 2026 guidance at 1.730-1.790 EPS and its FY 2026 guidance at 7.270-7.550 EPS. On average, sell-side analysts anticipate that Amdocs Limited will post 6.21 earnings per share for the current year.

Amdocs Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Tuesday, March 31st will be paid a $0.569 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $2.28 annualized dividend and a yield of 3.3%. This is an increase from Amdocs’s previous quarterly dividend of $0.53. Amdocs’s dividend payout ratio is 40.81%.

More Amdocs News

Here are the key news stories impacting Amdocs this week:

• Positive Sentiment: Amdocs announced a multi‑year strategic collaboration with Amazon Web Services to combine Amdocs’ aOS agentic operating system with AWS AI and cloud capabilities to drive telecom modernization — a material commercial & product endorsement that supports future revenue growth. MWC 2026: Amdocs and AWS Announce Multi-Year Strategic Collaboration to Accelerate AI-Driven Telecom Modernization
• Positive Sentiment: Amdocs announced a collaboration with Microsoft to deliver AI‑accelerated application modernization (Amdocs Agentic Services + Microsoft AI), which can expand enterprise services and upsell opportunities. MWC 2026: Amdocs Collaborates with Microsoft to Bring AI-Accelerated Application Modernization to Enterprises
• Positive Sentiment: Amdocs partnered with Google Cloud to combine Gemini Enterprise CX with Amdocs’ Cognitive Core to create an agentic telco contact center — another strategic cloud/A.I. endorsement that could help win telco transformation deals. MWC 2026: Amdocs Collaborates with Google Cloud to Accelerate AI Adoption and Power the Agentic Telco Contact Center
• Positive Sentiment: Zacks Research raised multiple near‑ and medium‑term EPS forecasts (including FY2026/FY2027/FY2028 upgrades and several quarterly raises), which supports a more constructive earnings outlook and could underpin valuation. See Zacks coverage for context. Amdocs (DOX) is a Top-Ranked Growth Stock: Should You Buy?
• Neutral Sentiment: Published short‑interest notices show zero reported short interest and anomalous “NaN” increases across several February reporting dates — this appears to be a data/reporting issue and implies no visible short‑squeeze pressure at present.
• Negative Sentiment: Zacks trimmed its Q2 2026 EPS estimate from $1.60 to $1.50 in the same round of updates — a modest near‑term earnings downgrade that could temper sentiment around the next quarter.
• Negative Sentiment: Technically, the share price is below both the 50‑day and 200‑day moving averages noted in recent quotes, which can invite short‑term selling/ profit‑taking even amid positive fundamental headlines.

About Amdocs

Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.

Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.